Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Development programme

LEADER — liraglutide cardiovascular outcomes

The cardiovascular outcome trial that first established a cardiovascular benefit for a GLP-1 receptor agonist in type 2 diabetes.

Sponsor class: Manufacturer-sponsored. First record: 2010.

Filter by text

Phase

Status

Showing 0 records on this page

Records in this programme

5 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
LEADER	Liraglutide	Phase 3	Reported	Event-driven cardiovascular outcome trial	9,340	2016	High
LEADER-BIOMARKERprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
LEADER-ELDERLYprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low
LEADER-OLEprogramme record	Liraglutide	Phase 3	Reported	Single-arm open-label	—	2016	Very low
LEADER-QOLprogramme record	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	—	2016	Very low

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.